Multi-turn medical question answering (QA) aims to model realistic clinical diagnosis, where a doctor gathers patient information across multiple turns of conversation. Existing multi-turn medical conversation systems have shown promising progress, but they often rely on accumulated conversation histories as memory, leaving clinical evidence fragmented across turns. We propose **GraphMed-LT**, a patient-specific graph memory approach with latent clinical thought refinement for multi-turn medical conversations. GraphMed-LT extracts patient-specific clinical triplets from patient responses, retrieves relevant knowledge triplets, and organises them into an incrementally updated graph memory. The graph memory is projected into graph-conditioned evidence tokens and refined inside a trainable doctor agent through hidden-state feedback, enabling the agent to update its internal clinical context before asking follow-up questions or producing the final answer. Experiments on three multi-turn medical QA benchmarks show that GraphMed-LT consistently outperforms existing multi-turn medical conversation baselines across multiple LLM backbones, achieving up to a 6.3 percentage-point absolute improvement over the strongest baseline. Further analyses show that GraphMed-LT asks more answerable follow-up questions and provides consistent gains across medical specialties.

Biomedical multi-hop question answering (QA) requires models to connect evidence across intermediate entities such as diseases, drugs, proteins, and phenotypes. Existing agents typically rely on static retrieval workflows or coarse-grained prompt rewriting, which can lead to instruction drift when reasoning procedures need to be updated. We propose **SSE-Bio**, a structured self-evolving agent with an agentic retrieval policy for multi-hop biomedical reasoning. Instead of globally rewriting agent instructions, SSE-Bio maintains a structured state, selectively retrieves knowledge triplets and prior templates through a trainable proxy policy, and improves its reasoning memory through fine-grained template editing. To optimise retrieval decisions, we introduce a proxy-training strategy based on group relative policy optimization, where the proxy is improved through decision-contrastive groups over alternative retrieval choices. Experiments on three biomedical multi-hop QA benchmarks show that SSE-Bio consistently outperforms existing baselines, achieving an improvement of 6.56 absolute points over the strongest self-evolving baseline on BioHopR.

Predicting drug-target interaction (DTI) is critical in the drug discovery process. Despite remarkable advances in recent DTI models through the integration of representations from diverse drug and target encoders, such models often struggle to capture the fine-grained interactions between drugs and protein, i.e. the binding of specific drug atoms (or substructures) and key amino acids of proteins, which is crucial for understanding the binding mechanisms and optimising drug design. To address this issue, this paper introduces a novel model, called FusionDTI, which uses a token-level Fusion module to effectively learn fine-grained information for Drug-Target Interaction. In particular, our FusionDTI model uses the SELFIES representation of drugs to mitigate sequence fragment invalidation and incorporates the structure-aware (SA) vocabulary of target proteins to address the limitation of amino acid sequences in structural information, additionally leveraging pre-trained language models extensively trained on large-scale biomedical datasets as encoders to capture the complex information of drugs and targets. Experiments on three well-known benchmark datasets show that our proposed FusionDTI model achieves the best performance in DTI prediction compared with eight existing state-of-the-art baselines. Furthermore, our case study indicates that FusionDTI could highlight the potential binding sites, enhancing the explainability of the DTI prediction.